Don't reduce chemotherapy dose for obese women with ER-negative breast Ca

Article

It seems obese breast cancer patients are frequently underdosed when it comes to chemotherapy.

It seems obese breast cancer patients are frequently underdosed when it comes to chemotherapy.

Researchers reviewed data from four randomized trials of the International Breast Cancer Study Group assessing the use of adjuvant classical chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in premenopausal women with node-positive breast cancer.

They found that 39% of obese women received less than 85% of the chemotherapy dose specified by the protocol versus 16% of women with normal or intermediate body mass index. While this didn't significantly compromise outcome in the women with estrogen-receptor (ER)–positive disease, reducing the dose of chemotherapy was associated with a significantly worse outcome in the obese women with ER-negative cancer in terms of disease-free survival (total population hazards ratio ≥ 85% vs. <85%, 0.68, 95% CI; 0.54–0.86, P=0.0013) and overall survival (0.72, 0.56-0.94, P=0.0142).

Recent Videos
1 expert is featured in this series.
Giovanni Traverso, PhD, highlights contraceptive implants through small needle | Image Credit: meche.mit.edu
Ryan Haumschild, PharmD
1 expert is featured in this series.
How sex differences impact treatment efficacy for chronic pain | Image Credit: profiles.ucalgary.ca.
Tuan Trang, PhD, discusses biological differences in chronic pain between men and women | Image Credit: profiles.ucalgary.ca.
1 expert is featured in this series.
How the Flyte device revolutionizes SUI management | Image Credit: linkedin.com.
Dr. Wanda Filer discusses how to overcome barriers to SUI treatment | Image Credit: linkedin.com.
Revi System shows efficacy against urgency urinary incontinence | Image Credit: ics.org.
© 2025 MJH Life Sciences

All rights reserved.